Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005

被引:13
作者
Ferraris, Olivier [1 ]
Kessler, Nicole [1 ]
Valette, Martine [1 ]
Lina, Bruno [1 ]
机构
[1] Domaine Rockefeller, Ctr Natl Refernece Grippe, Virol Lab, F-69373 Lyon 08, France
关键词
influenza; inhibitors; neuraminidase deficient;
D O I
10.1016/j.vaccine.2006.05.050
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 2002, prior to the generalization of zanamivir and oseltamivir utilization in France, we had decided to test a large panel of influenza strains to establish the baseline sensitivity of these viruses to anti-neuraminidase drugs. Since 2002, routine monitoring of resistance relies mainly on the results of neuraminidase enzyme assay. The profile of sensitivity of A/H3N2 viruses has not changed during these three influenza seasons. Neuraminidase N2 was shown to be more sensitive to oseltamivir carboxylate than to zanamivir. Amongst 788 viruses tested, only 10 were found with outliers IC50 values (seven in 2003, one in 2004, and two in 2005). After the sequencing of the neuraminidase segment of these viruses, seven mutations on the stalk or the head of the glycoprotein (A18S, L23F, C42R, R143V, E199K, S332K, R431N) were detected. Moreover during seasons 2003-2005, 12 additional viruses were characterized by a complete lack of neuraminidase activity. In these viruses, viral resistance to NA inhibitors can be related with the presence of a defective neuraminidase RNA segment as evaluated by a plaque reduction assay, these viruses having a reduced dependence on its neuraminidase activity. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6656 / 6659
页数:4
相关论文
共 8 条
[1]  
AYMARDHENRY M, 1973, B WORLD HEALTH ORGAN, V48, P199
[2]   Sensitivity performed of influenza viruses to zanamivir and oseltamivir: A study on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice [J].
Ferraris, O ;
Kessler, N ;
Lina, B .
ANTIVIRAL RESEARCH, 2005, 68 (01) :43-48
[3]   A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site [J].
Gubareva, LV ;
Nedyalkova, MS ;
Novikov, DV ;
Murti, KG ;
Hoffmann, E ;
Hayden, FG .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :2683-2692
[4]   Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice [J].
Hughes, MT ;
Matrosovich, M ;
Rodgers, ME ;
McGregor, M ;
Kawaoka, Y .
JOURNAL OF VIROLOGY, 2000, 74 (11) :5206-5212
[5]   Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071 [J].
Li, WX ;
Escarpe, PA ;
Eisenberg, EJ ;
Cundy, KC ;
Sweet, C ;
Jakeman, KJ ;
Merson, J ;
Lew, W ;
Williams, M ;
Zhang, LJ ;
Kim, CU ;
Bischofberger, N ;
Chen, MS ;
Mendel, DB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :647-653
[6]   Surveillance of community-acquired viral infections due respiratory viruses in Rhone-Alpes (France) during winter 1994 to 1995 [J].
Lina, B ;
Valette, M ;
Foray, S ;
Luciani, J ;
Stagnara, J ;
See, DM ;
Aymard, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (12) :3007-3011
[7]   INFLUENZA TYPE-A VIRUS NEURAMINIDASE DOES NOT PLAY A ROLE IN VIRAL ENTRY, REPLICATION, ASSEMBLY, OR BUDDING [J].
LIU, CG ;
EICHELBERGER, MC ;
COMPANS, RW ;
AIR, GM .
JOURNAL OF VIROLOGY, 1995, 69 (02) :1099-1106
[8]   RATIONAL DESIGN OF POTENT SIALIDASE-BASED INHIBITORS OF INFLUENZA-VIRUS REPLICATION [J].
VONITZSTEIN, M ;
WU, WY ;
KOK, GB ;
PEGG, MS ;
DYASON, JC ;
JIN, B ;
PHAN, TV ;
SMYTHE, ML ;
WHITE, HF ;
OLIVER, SW ;
COLMAN, PM ;
VARGHESE, JN ;
RYAN, DM ;
WOODS, JM ;
BETHELL, RC ;
HOTHAM, VJ ;
CAMERON, JM ;
PENN, CR .
NATURE, 1993, 363 (6428) :418-423